The present invention relates to a myocardial spectrometer probe, comprising: at least two separate light guides (120A, 120B), insertable in a tissue, wherein a first light guide (120A, 120B) is arranged to deliver light and a second light guide (120A, 120B) is arranged to collect light, and wherein the first light guide (120A, 120B) and the second light guide (120A, 120B) are arranged distinct to each other.

An electrically conductive connection element for a temporary electrically conductive connection to an electrical consumer, in particular an external pacemaker, which is implanted in the living tissue of a patient, may have at least one biocompatible and bioresorbable electrical conductor strand in the form of an individual wire or a multifilament formed by multiple wires. The at least one electrical conductor strand is surrounded by at least one biocompatible and bioresorbable polymer or is embedded in a matrix formed by the polymer.

Brugada syndrome and related forms of ion channelopathies, including ventricular asynchrony of contraction, originate in the region near the His bundle or para-Hisian regions of the heart. Manifestations of Brugada syndrome can be corrected by delivering endocardial electrical stimulation coincident to the activation wave front propagated from the atrioventricular (AV) node. By performing the start of the activation of the HIS bundle or para-Hisian region early enough, electrical stimulation can be delivered fast enough to compensate for the conduction problems that start in those region, such that the activation wave front, as stimulated, transitions from the AV node to the His bundle in a normal, albeit electrically-supplemented, fashion. This stimulation not only helps resolve the conditions that trigger Brugada syndrome, but also resolves the asynchrony of the contraction of the heart.

A stimulation system includes an energy source, an electronics unit with a controller, and an actuator that is coupled with the electronics unit and/or the energy source. The actuator emits electromagnetic waves for stimulation of genetically manipulated tissue. The electronics unit is disposed in a housing. The stimulation system is configured for at least temporary implantation in a human or animal body. The controller controls the stimulation of tissue in the body by way of the electromagnetic waves emitted by the actuator. A selector of the stimulation system selects the area of the said tissue for stimulation. The selector includes a masking device for masking certain areas of the tissue, so that an intensity of the stimulation for the masked areas is reduced or equal to zero.

An apparatus for monitoring a patient post operation having electrically conducting leads which are adapted to extend from inside the patient. The leads having electrodes adapted to communicate with a heart of the patient and apply electrical signals to the heart. The electrodes providing cardiac signals to the computer in response to the electrical signals so the computer can determine in real time at least one of heart volume, end diastolic heart volume, end systolic heart volume, stroke volume, change in heart volume, change in stroke volume, contractility, respiration rate or tidal volume regarding the patient.

Brugada syndrome and related forms of ion channelopathies, including ventricular asynchrony of contraction, originate in the region near the His bundle or para-Hisian regions of the heart. Manifestations of Brugada syndrome can be corrected by delivering endocardial electrical stimulation coincident to the activation wave front propagated from the atrioventricular (AV) node. By performing the start of the activation of the HIS bundle or para-Hisian region early enough, electrical stimulation can be delivered fast enough to compensate for the conduction problems that start in those region, such that the activation wave front, as stimulated, transitions from the AV node to the His bundle in a normal, albeit electrically-supplemented, fashion. This stimulation not only helps resolve the conditions that trigger Brugada syndrome, but also resolves the asynchrony of the contraction of the heart.

A device, system, and method for delivering energy to tissue. In particular, the present invention relates to a system and method for enhancing lesion formation without arrhythmogenic effects within relatively thick target tissues, such as the ventricles of the heart. In one embodiment, charge-neutral pulses and non-charge-neutral pulses may be delivered to induce the formation of electrolytic compounds that enhance cell death at the treatment site. Additionally or alternatively, tissue at the treatment site may be heated to sub-lethal temperature before ablating the tissue.

An apparatus for monitoring a patient post operation having electrically conducting leads which are adapted to extend from inside the patient. The leads having electrodes adapted to communicate with a heart of the patient and apply electrical signals to the heart. The electrodes providing cardiac signals to the computer in response to the electrical signals so the computer can determine in real time at least one of heart volume, end diastolic heart volume, end systolic heart volume, stroke volume, change in heart volume, change in stroke volume, contractility, respiration rate or tidal volume regarding the patient.

An implantable device for implantation in a human body or animal body. The device includes an energy source, an energy storage device, and an electronics unit. Further, an actuator is coupled with the energy storage device and it is configured to emit electromagnetic waves by discharging the energy storage device.

An interface for coupling with a percutaneously implantable lead is described. The interface includes a rotation based system to engage the terminal connector of the lead. The interface includes a brake which retains the lead in the lead port through friction, but allows the lead to exit the lead port if sufficient force is applied. The interface can be coupled with the lead without removing a stylet or stiffening wire from the lead.